Karavela Inc.

Based in France, Karavela Inc. specializes in advanced magnetic resonance imaging technology, focusing on developing a comprehensive foundation model of human brain dynamics through innovative MRI studies. Karavela Inc. was founded in 2025 and is headquartered in Paris, France.

The company utilizes its expertise in magnetic resonance imaging to conduct extensive brain studies, attracting healthy volunteers to build a robust dataset for clinical research. In October 2025, Karavela raised EUR 2 million in pre-seed funding from investors including HCVC, Daphni, and First Momentum Ventures. Karavela specializes in advanced magnetic resonance imaging technology aimed at creating a comprehensive foundation model of the human brain's dynamics. Their core offering encompasses a large-scale brain MRI study, Cephalonauts One, which invites healthy volunteers to participate, thereby contributing to a substantial dataset for clinical research.

This initiative seeks to enhance clinical trials through artificial intelligence and facilitate breakthroughs in brain decoding, with a focus on regions rich in research infrastructures and commitment to neurological studies, such as North America and parts of Europe. Karavela's revenue generation model is rooted in participation agreements for their MRI study and potential collaborations with research institutions and pharmaceutical companies. Transactions occur through direct engagement with volunteers and partnerships with clinical organizations that utilize the data collected for various applications, including drug development and neurological assessments. The firm may offer tiered pricing structures for access to their datasets or collaborative research opportunities, creating avenues for institutional subscriptions or direct-to-consumer engagements within the healthcare sector.

In October 2025, Karavela raised EUR 2 million in funding to support team expansion, international MRI data partnerships, and the development of its first brain foundation model. The company plans to launch new MRI studies targeting specific global markets, particularly in North America and Europe, within the next year.